Regentis Biomaterials (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

Published Sep 14, 2026, 4:09 PM

Researchers across the field, from Duke University to Mayo Clinic, are increasingly focused on restoring damaged cartilage rather than simply managing the symptoms associated with its loss.
Regentis Biomaterials’ GelrinC is designed to support the body’s natural cartilage-regeneration process through a gradual, controlled repair environment.
Early clinical data has provided encouraging evidence for GelrinC, which already has approval in Europe, while an FDA-authorized pivotal trial is advancing its development toward potential U.S. approval.

A knee that once carried a runner through marathons or a hiker up a steep mountainside can be sidelined by a single defect in cartilage. More broadly, nearly a half-million Americans end up with knee cartilage damage each year as a result of long-term wear and tear and every-day accidents. For decades, many available treatments have focused on managing pain and restoring functions rather than actually replacing damaged cartilage with healthy tissue. Regentis Biomaterials (NYSE American: RGNT) is pursuing a different approach with GelrinC, an off-the-shelf hydrogel implant designed to support the regeneration of cartilage within the damaged area.

Cartilage is very difficult for the body to repair on its own. Unlike many other tissues, it has limited blood supply, which can make significant injuries difficult to heal and leave patients vulnerable to persistent pain, stiffness and progressive joint degeneration. Researchers across the field, including teams at Duke University and the Mayo Clinic, have been exploring ways to encourage…